Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
-
J. Oral Pathol. Med. · Mar 2012
Randomized Controlled Trial Multicenter Study Comparative StudyThe antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial.
Cytotoxic chemotherapy induces changes in the oral microflora that may cause oral and systemic infections in myelosuppressed cancer patients. These complications prompted us to assess the antimicrobial activity of a topical Iseganan HCl mouthwash vs. placebo on the aerobic and facultatively anaerobic oral flora in these patients. ⋯ Topical Iseganan HCl significantly reduces the total oral aerobic bacterial, streptococcal, and yeast load. Its potential as an oral antimicrobial agent in preventing these types of infections is clear.
-
J. Oral Pathol. Med. · Mar 2012
Randomized Controlled Trial Comparative StudyEvaluation of the clinical efficacy of a betaine-containing mouthwash and an intraoral device for the treatment of dry mouth.
An evaluation is made of the efficacy and safety of an intraoral device with a betaine (BET)-containing mouthwash in treating xerostomia. ⋯ The daily use of a night guard and BET-containing mouthwash was seen to improve dry mouth during the 4-week duration of the study.
-
J. Oral Pathol. Med. · Jan 2009
Randomized Controlled Trial Comparative StudyA case-control study on etiological factors involved in patients with burning mouth syndrome.
To evaluate and analyze the risk factors for burning mouth syndrome (BMS). ⋯ Our study indicated that BMS may be of psychological origin, and the measures such as refraining from oral parafunctional activities, removing local irritating factors, stopping smoking, good mental health status could help in the prevention of BMS.
-
J. Oral Pathol. Med. · Feb 2004
Randomized Controlled Trial Clinical TrialSystemic capsaicin for burning mouth syndrome: short-term results of a pilot study.
Burning mouth syndrome (BMS) is a major diagnostic and therapeutic problem. Systemic and topical treatments (capsaicin, lidocaine, anti-histamines, sucralfate and benzydiamine) have been tried, but they appear to be inadequate. Topical capsaicin is bitter, may cause burning and has low therapeutic efficacy. We hypothesized that systemic administration of capsaicin could reduce the limitations of topical administration and have better therapeutic efficacy; this hypothesis was tested in a controlled trial. ⋯ Systemic capsaicin is therapeutically effective for the short-term treatment of BMS but major gastrointestinal side-effects may threaten its large-scale, long-term use. This preliminary study suggests that more, adequately powered, randomized controlled trials are necessary and worthy to come to a definitive assessment of this matter.